## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.1% below STRENGTH zone (4.0-10.0%); PEG 3.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (41% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($552.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. ISRG Pre-Market (29 Dec 2025): Innovations in AI Surgical Systems**
- Source: Meyka | 20251229T151826 | Bullish | Relevance: 100%
- Intuitive Surgical, Inc. (NASDAQ: ISRG) is leveraging AI technologies to improve precision and outcomes in minimally invasive surgeries with its da Vinci and Ion systems. The company has shown robust growth with a 34.13% increase in stock price over the last month, a P/E ratio of 76.43, and reported revenue of USD 2.24 billion last quarter. Meyka AI rates ISRG with an 'A' grade and a 'BUY' recommendation, forecasting potential growth to USD 607.53 in the next month and USD 757.26 in five years.

**2. Those Who Invested in Intuitive Surgical (NASDAQ:ISRG) Three Years Ago Are up 117%**
- Source: 富途牛牛 | 20251231T020827 | Bullish | Relevance: 100%
- Investors who bought shares in Intuitive Surgical (NASDAQ:ISRG) three years ago have seen a substantial return of 117%. This performance is closely aligned with the company's 26% compound earnings per share growth over the same period, suggesting consistent market sentiment. The article also notes a 29% increase in the last quarter and a five-year annual TSR of 17%, indicating a strong long-term track record.

**3. Intuitive Surgical, Inc. $ISRG Shares Sold by Mirova US LLC**
- Source: MarketBeat | 20251230T130801 | Neutral | Relevance: 100%
- Mirova US LLC reduced its stake in Intuitive Surgical (NASDAQ:ISRG) by 3.4% in the third quarter, now owning 548,599 shares valued at $245.35 million. Despite insider sales totaling $63.53 million last quarter, analysts maintain a "Moderate Buy" rating with a consensus target price of $611.08. Intuitive Surgical also surpassed Q3 earnings estimates with EPS of $2.40 and revenue of $2.51 billion, a 22.9% year-over-year increase.

**4. Kieckhefer Group LLC Boosts Stock Holdings in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251230T124528 | Somewhat-Bullish | Relevance: 100%
- Kieckhefer Group LLC significantly increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 34.1% in the third quarter, now holding 14,540 shares valued at $6.50 million, making it their sixth-largest position. This increase occurred despite substantial insider selling totaling over $63.5 million from executives like Gary S. Guthart and Henry L. Charlton. Intuitive Surgical recently surpassed earnings estimates with Q3 revenue of $2.51 billion and EPS of $2.40, and analysts maintain a "Moderate Buy" rating with an average target price around $611.

**5. Intuitive Surgical and the Robot That Rewrote Surgery**
- Source: AD HOC NEWS | 20251230T111712 | Bullish | Relevance: 100%
- Intuitive Surgical has fundamentally transformed operating rooms with its da Vinci robotic systems, making minimally invasive surgery the standard for precision and data-driven care. The company's comprehensive ecosystem, including advanced robotics, software, and training, gives it a significant competitive edge over rivals like Medtronic and Johnson & Johnson. Intuitive Surgical's strong market position is driven by its expanding installed base, increasing procedure volumes, and recurring revenue model, reinforcing its status as a leader in robotic-assisted surgery.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.55 signals overvaluation risk, limited margin of safety. Forward P/E 58.7x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $205.3B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.55 |
| Forward P/E | 58.7 |
| Current P/E | 66.3 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 1.1% (minimal 5-day change). Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Volume at 41% of 20MA suggests lack of conviction. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.06% (CS: 67) | Neutral |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.122x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $572.63
- **Stop Loss:** $552.37 (3.5% risk)
- **Target:** $592.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $37,220.95
- **Portfolio %:** 37.22%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*